Visible light-activatable platinum( iv ) prodrugs harnessing CD36 for ovarian cancer therapy

Authors:

Abstract
Visible light-activatable Pt( iv ) prodrugs harness the upregulated CD36 to facilitate cell entry and killing of drug resistant ovarian cancer cells.
Funding Information
  • Kent State University (PAA-0213)
  • Kent State University (Healthy Communities Research Institute)
  • Basic Energy Sciences (DE-SC0016501)
  • National Cancer Institute (1R15CA249712-01A1)

This publication has 40 references indexed in Scilit: